The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Record quarterly results were driven by broad-based growth across all three segments, fueled by market penetration of specialty nutrients and 'better-for-you' food trends.

Human Nutrition and Health (HNH) performance was bolstered by heightened consumer interest in high-protein, high-fiber, and lower-sugar products.

Animal Nutrition and Health (ANH) saw significant margin improvement and 15% sales growth, aided by the adoption of encapsulated rumen-protected technologies in the dairy market.

The European monogastric business realized higher volumes and margins following the implementation of EU antidumping duties, which restored a level playing field.

Specialty Products growth was primarily supported by solid volume and pricing gains within the performance gases business.

Management mitigated higher input costs stemming from Middle East conflicts through strategic pricing actions and growth-driven operating leverage.

Management expects continued growth in HNH by leveraging an 'always-on' consumer engagement model and targeting specific demographics like GLP-1 users.

The company anticipates the publication of a pilot clinical study on choline's impact on Alzheimer's and dementia, which could drive significant future demand.

Capital allocation remains focused on a balanced approach, including innovation, capacity expansion, and strategic acquisition opportunities supported by a new $650 million credit facility.

The effective tax rate for the remainder of 2026 is projected to trend between 22.5% and 23%.

Future growth in the ruminant portfolio is expected to be driven by volume as the company continues to build science-based awareness for its precision-release technologies.

Completed a refinancing of the revolving credit facility, increasing capacity to $650 million and extending maturity to 2031 with improved pricing grids.

Repurchased approximately $29 million of common stock during the quarter, totaling $114 million over the trailing 12 months.

The effective tax rate increased to 22.8% from 21.9% in the prior year, primarily due to lower tax benefits from stock-based compensation.

Net debt stands at $89 million with a low leverage ratio of 0.3, providing significant flexibility for future M&A.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management prioritizes products with sound existing science and clear points of differentiation, such as unique encapsulation or patent protection.

The company targets 'niche' nutrients with low market awareness to drive above-market growth through education and penetration.

The decision to build versus buy depends on proximity to core technology; internal development is preferred for adjacent technologies, while acquisitions are used for distinct platforms.

Balchem maintains 20 to 25 ongoing studies to provide customers with scientific evidence for product claims and marketing.

A key study with MD Anderson on adult cognition and the APOE4 gene is completed and expected to be published within the next few months.

Positive results from the choline-cognition study are expected to lead to larger, more definitive trials to reinforce the nutrient's clinical value.

The company has shifted toward an omnichannel model including influencer engagement and sports partnerships, generating over a billion impressions in 18 months.

Marketing efforts are being dynamically adjusted to target GLP-1 users for snacks and meal replacements as consumer behaviors evolve.

Growth was roughly split between volume and pricing, with the ruminant business specifically seeing 20% growth driven almost entirely by volume.

The European recovery is progressing as expected, with share gains and price recovery continuing every quarter since the antidumping duties began.